ATM and non-small cell lung carcinoma: TP53 is frequently mutated in cancer, and the ATM pathway is down-regulated in many solid tumors: 11% of NSCLC carry somatic mutations in ATM and 41% of LUAD and 75% of BC have reduced ATM protein expression (Angèle et al, 2003; Ding et al, 2008; Cancer Genome Atlas Research Network, 2012; Imielinski et al, 2012; Rondeau et al, 2015; Villaruz et al, 2016).